Lapatinib Tablets, 250 mg, are the generic equivalent of Tykerb® Tablets, 250 mg, of Novartis Pharmaceutical Corporation, and are indicated in combination with:
- Capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2), and who have received prior therapy including an anthracycline, a taxane and trastuzumab
- Letrozole for the treatment of postmenopausal women with hormone-receptor positive metastatic breast cancer that overexpresses the HER2 receptor, for whom hormonal therapy is indicated
Lapatinib Tablets (RLD: Tykerb®) had annual sales of approximately USD 61 million in the U.S. (IQVIA MAT June 2020).
Attention Investors
1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
2. Update your mobile number & email Id with your Stock Broker/Depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
3. Pay 20% upfront margin of the transaction value to trade in cash market segment.
4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 & 20200731-7 dated July 31, 2020 and NSE/INSP/45534 & 20200831-45 dated August 31, 2020 and other guidelines issued from time to time in this regard.
5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.